Adaptive, iterative, long-term personalized therapy management in a case of stage IV refractory NSCLC
In this paper we report long-term therapy management based on iterative de novo molecular
and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior …
and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior …
Duration of Targeted Therapy in Patients with Advanced Non–Small-Cell Lung Cancer Identified by Circulating Tumor DNA Analysis
Background Outcomes of therapy targeting molecular driver alterations detected in
advanced non–small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been …
advanced non–small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been …
Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based …
J Remon, A Swalduz, D Planchard, S Ortiz-Cuaran… - PLoS …, 2020 - journals.plos.org
Circulating tumor DNA (ctDNA)-based molecular profiling is rapidly gaining traction in
clinical practice of advanced cancer patients with multi-gene next-generation sequencing …
clinical practice of advanced cancer patients with multi-gene next-generation sequencing …
Concurrent Circulating Tumor DNA and Tissue Genotyping—Ready for Prime Time?
BA Bleiberg, C Aggarwal - JAMA Network Open, 2024 - jamanetwork.com
Molecularly directed targeted therapies have become a key component of caring for patients
with metastatic solid tumors, both alongside and instead of conventional chemotherapy and …
with metastatic solid tumors, both alongside and instead of conventional chemotherapy and …
[HTML][HTML] Precision treatment for metastatic non–small cell lung cancer: A conceptual overview
T Lee, JM Clarke, D Jain, S Ramalingam… - Cleveland Clinic Journal …, 2021 - ccjm.org
Recent developments in precision oncology have increased the complexity of diagnostic
and therapeutic decisions. Here, we broadly review the field of precision oncology and …
and therapeutic decisions. Here, we broadly review the field of precision oncology and …
Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.
8518 Background: Detection of circulating tumor DNA (ctDNA) has prognostic value in lung
cancer and could facilitate minimal residual disease (MRD) driven approaches. However …
cancer and could facilitate minimal residual disease (MRD) driven approaches. However …
NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
AT Falk, S Heeke, V Hofman, V Lespinet… - Expert review of …, 2017 - Taylor & Francis
Introduction: The advent of genomic based precision medicine led to the implementation of
biomarker testing in metastatic non-small cell lung cancer (NSCLC) patients. Next …
biomarker testing in metastatic non-small cell lung cancer (NSCLC) patients. Next …
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …
Sequencing Therapy for Genetically Defined Subgroups of Non–Small Cell Lung Cancer
The practice of precision medicine for patients with metastatic non–small cell lung cancer
(NSCLC), particularly those patients with adenocarcinoma histology (the predominant …
(NSCLC), particularly those patients with adenocarcinoma histology (the predominant …
The BATTLE trial: personalizing therapy for lung cancer
Abstract The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer
Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated …
Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated …